Splitomicin (CAS 5690-03-9)

Splitomicin, a compound of interest in scientific research, has been investigated primarily for its role as a specific inhibitor of the enzyme sirtuin 2 (SIRT2). Its mechanism of action involves binding to the catalytic site of SIRT2, inhibiting its deacetylase activity. SIRT2 belongs to the sirtuin family of NAD+-dependent protein deacetylases, which play crucial roles in regulating various cellular processes such as gene expression, metabolism, and stress response. Research utilizing splitomicin has provided insights into the functions of SIRT2 and its involvement in cellular physiology and pathology. Studies have employed splitomicin to investigate the impact of SIRT2 inhibition on cellular processes such as cell cycle progression, cytoskeleton dynamics, and autophagy. Furthermore, splitomicin has been utilized in experimental models to explore the potential of targeting SIRT2 in diseases such as cancer, neurodegenerative disorders, and metabolic syndromes. Additionally, splitomicin serves as a valuable tool in dissecting the molecular mechanisms underlying sirtuin-mediated signaling pathways and identifying potential targets for pharmacological intervention. Overall, splitomicin represents an important asset in biomedical research, offering opportunities to explain the roles of sirtuins in health and disease.